% | $
Quotes you view appear here for quick access.

OXiGENE, Inc. Message Board

  • vvvvvvrebel89130 vvvvvvrebel89130 Mar 29, 2014 5:48 PM Flag

    big sound familiar?

    i suspect ecyt won't present at aacr for ovarian
    i read multiple articles on ecyt on their yahoo news page; its scary how similar oxgn and ecyt are except for the valuation

    these 3 abstracts being presented at aacr are important as they show continued progress in the rest of the pipeline which was mentioned multiple times in the ecyt articles


    In NSCLC, Endocyte tested the drug alone and in combination with docetaxel, with a group receiving docetaxel alone for comparison. The trial met the predefined threshold for statistical significance of achieving a p-value of less than 0.10 for its progression-free survival (PFS) endpoint. However, the company did not break down the numbers for survival or report on secondary endpoints (including overall survival), saying that it would present those results at an upcoming medical conference.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.66+0.03(+3.94%)May 27 4:00 PMEDT